Boston Pharma's Activities • Friday, 25/02/2022 - 10:47 (GMT+7)


At the end of January 2020, since the time when the COVID-19 epidemic first appeared in Vietnam, it has caused heavy losses to the health, life of the people and the economy of the country.

In particular, the 4th outbreak from April 27, 2021 with the Delta mutation has reversed and changed everything in epidemic prevention in Vietnam.

Boston pharma with the criterion of putting product quality first and accompanying public health care, since September 2021, the company has devoted all of its efforts to research and manufacture the drug Molravir 400 (active ingredient molnupiravir 400 mg) and on February 17, 2022, Molravir 400 was officially licensed for circulation by the Drug Administration of Vietnam, the Ministry of Health.

Figure 1. Finished product overview

Representative of Boston VN affirmed:“The research phase faced many difficulties and the company's staff has worked tirelessly for the past 4-5 months to ensure that each pill produced must be of high quality and effective for patients. In addition, the company continues to research and develop other products to treat Covid-19."

Figure 2. Research and production of drugs at the Boston Pharma factory

The finished product Molravir 400, before being put on the market, is stored under normal conditions (below 30 degrees Celsius), the drug is also studied and evaluated for stability in extreme conditions (60 degrees Celsius) and accelerated aging (40 degrees Celsius) to ensure drug quality during circulation.

Figure 3. Monitoring parameters of accelerated aging prevention

Each blister of Molaravir 400 is laminated with aluminum ALU_ALU on both sides to prevent light, moisture and keep the drug's quality and stability.

Figure 4. Inside the blister pack of Molaravir

The company's research process also has the review of records and prompt response from the Drug Administration.

Figure 5. The back of the pack when finished

The company's production line can produce 2 million tablets per day, equivalent to 100,000 courses (20 tablets each). Molravir 400 products are distributed by Boston Pharma and sold at drugstores at reasonable prices, helping patients to easily access medicines and jointly protect public health in the prevention of the Covid-19 epidemic.

The product Molravir 400 (active ingredient Molnupiravir 400mg) is officially licensed for circulation in Vietnam by the Ministry of Health.

- Colour hard capsules (Preventing from direct light)

- Alu-Alu for blister packaging Environmental factors resistance (Light, Humidity)

- Reasonable and stable price

- Transparent at Boston Sale app

- Ensure adequate product supply

- See more product details at:

Source: |